Verrica appoints Charles Frantzreb to board, grants performance-based options to CEO

Verrica Pharmaceuticals Inc.

Charles Frantzreb, Partner at Caligan, appointed to board effective Dec 26, 2025; Class III director term to 2027 annual meeting.
CEO Jayson Rieger granted options for 512,269 shares at $8.21, vesting on stockholder plan amendment and stock price milestones of $15 and $25.
Interim CFO John Kirby granted 10,000 fully vested RSUs on Dec 23, 2025.
Frantzreb designated by Caligan under Securities Purchase Agreement dated Nov 23, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.